Incidence and predictors of reinfection with trichomoniasis based on nucleic acid amplification testing results in HIV-infected patients.


Journal

International journal of STD & AIDS
ISSN: 1758-1052
Titre abrégé: Int J STD AIDS
Pays: England
ID NLM: 9007917

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 30 11 2018
medline: 27 9 2019
entrez: 30 11 2018
Statut: ppublish

Résumé

Trichomonas vaginalis infection contributes to HIV transmission. The study objective was to determine the incidence and predictors of T. vaginalis reinfection among HIV-infected women in Birmingham, Alabama. A retrospective cohort study of women at an urban HIV clinic from August 2014 to March 2016 with T. vaginalis by nucleic acid amplification test (NAAT) was conducted. Time to first episode of reinfection was evaluated using Kaplan-Meier survival curves. The association of various predictors was evaluated by univariate and multivariable Cox proportional hazards analyses. Of 612 HIV-infected women at the UAB HIV clinic tested for T. vaginalis by the Aptima TV assay, 110 (18.0%) were identified with prevalent T. vaginalis infection. Overall, 25/110 (22.7%) had a first episode of T. vaginalis reinfection by NAAT with a rate of 3.7 reinfections per 100 person-months (95% confidence interval [CI]: 2.3, 5.2). In univariate analysis, only an HIV viral load (VL) ≥200 copies/ml approached statistical significance (hazard ratio = 2.26; 95% CI: 0.97, 5.29, p = 0.06). After adjusting for age and race, the association of HIV VL ≥200 copies/ml remained strong (adjusted hazard ratio = 2.49; 95% CI: 0.99, 6.27, p = 0.05). T. vaginalis reinfection was high among HIV-infected women in this sample, necessitating enhanced disease control efforts in this high-risk population.

Identifiants

pubmed: 30486764
doi: 10.1177/0956462418807115
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

344-352

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI106957
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL126570
Pays : United States
Organisme : AHRQ HHS
ID : K12 HS023009
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027767
Pays : United States

Auteurs

Christina A Muzny (CA)

1 Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.

Ashutosh R Tamhane (AR)

1 Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.

Ellen F Eaton (EF)

1 Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.

Kathryn Hudak (K)

2 University of Alabama School of Medicine, Birmingham, AL, USA.

Greer A Burkholder (GA)

1 Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.

Jane R Schwebke (JR)

1 Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH